The invention refers to a stable antibody formula for a predetermined death receptor of PD-1 human or a fixed fragment of PD-1 antigen. In some embodiments, the formula of the invention includes 5 to 200 mg / ml of anti-PD-1 antibody or a fixed fragment of 5 Oriental antigen. The invention also provides a method for treating different types of cancer with a stable invention formula. In some ways of realizing the invention method,The formula is given to patients by intravenous injection or subcuta. Nea.The Invention relates to stable formulations of antiodies against human programmed death received PD-1，or antigen binding fragments thereof. In some embediments the formulations of the invention comprise between 5-200 mg/ml anti-pd-1 antiody，or antigien binding fragment there. The invention further provides a method for treating various cancers, including a stable formula of the invention. In some defects of the invention and creation method, these expressions are managed by internal or secondary administrative departments on a subject.La invención se refiere a formulaciones estables de anticuerpos contra el receptor de muerte programada humano PD-1, o fragmentos de fijación al antígeno de este. En algunas formas de realización, las formulaciones de la invención comprenden entre 5 y 200 mg/ml de anticuerpo anti-PD-1, o un fragmento de fijación al antígeno de 5 este. La invención además proporciona métodos para tratar distintos tipos de cáncer con formulaciones estables de la invención. En algunas formas de realización de los métodos de la invención, las formulaciones se administran a un sujeto mediante administración intravenosa o subcutánea.The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treati
